These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36114896)

  • 1. Correction to: Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy.
    Kawakubo K; Fernández-Del Castillo C; Liss AS
    J Gastroenterol; 2022 Nov; 57(11):827. PubMed ID: 36114896
    [No Abstract]   [Full Text] [Related]  

  • 2. Algenpantucel-L immunotherapy in pancreatic adenocarcinoma.
    Coveler AL; Rossi GR; Vahanian NN; Link C; Chiorean EG
    Immunotherapy; 2016 Feb; 8(2):117-25. PubMed ID: 26787078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects].
    Ye C; Zheng L; Yuan CH
    Zhonghua Wai Ke Za Zhi; 2019 Jan; 57(1):10-15. PubMed ID: 30612387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapeutic approach for advanced pancreatic adenocarcinoma.
    Kaur J; Mir T; Gill R; Duong J; Marcus S; Khan R
    Immunotherapy; 2021 Jun; 13(9):767-782. PubMed ID: 33910383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency.
    Pang X; Qian J; Jin H; Zhang L; Lin L; Wang Y; Lei Y; Zhou Z; Li M; Zhang H
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Advances in immunotherapy of pancreatic ductal adenocarcinoma].
    Yang JQ; Wei T; Chen YW; Bai XL; Liang TB
    Zhonghua Wai Ke Za Zhi; 2017 May; 55(5):396-400. PubMed ID: 28464583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy.
    Smith C; Zheng W; Dong J; Wang Y; Lai J; Liu X; Yin F
    World J Gastroenterol; 2022 Jul; 28(27):3297-3313. PubMed ID: 36158269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in immunotherapy for pancreatic ductal adenocarcinoma.
    Miyazawa M; Katsuda M; Kawai M; Hirono S; Okada KI; Kitahata Y; Yamaue H
    J Hepatobiliary Pancreat Sci; 2021 May; 28(5):419-430. PubMed ID: 33742512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
    Blair AB; Zheng L
    Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of pancreatic cancer.
    Sunami Y; Kleeff J
    Prog Mol Biol Transl Sci; 2019; 164():189-216. PubMed ID: 31383405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and clinical significance of placenta-specific 1 in pancreatic ductal adenocarcinoma.
    Yin Y; Zhu X; Huang S; Zheng J; Zhang M; Kong W; Chen Q; Zhang Y; Chen X; Lin K; Ouyang X
    Tumour Biol; 2017 Jun; 39(6):1010428317699131. PubMed ID: 28618924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A subset of epithelial cells mimics regulatory T cells and contributes to immune evasion during development of pancreatic adenocarcinoma.
    Houchen CW; Li M
    BMC Med; 2020 Jun; 18(1):155. PubMed ID: 32594906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine.
    Gerber MH; Underwood PW; Judge SM; Delitto D; Delitto AE; Nosacka RL; DiVita BB; Thomas RM; Permuth JB; Hughes SJ; Wallet SM; Judge AR; Trevino JG
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective analysis of the National Cancer Database.
    Amin S; Baine M; Meza J; Alam M; Lin C
    Radiat Oncol; 2020 Jun; 15(1):139. PubMed ID: 32493354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions.
    Tan E; El-Rayes B
    J Gastrointest Cancer; 2019 Mar; 50(1):1-8. PubMed ID: 30446922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Association of the Sequence of Immunotherapy With the Survival of Unresectable Pancreatic Adenocarcinoma Patients: A Retrospective Analysis of the National Cancer Database.
    Amin S; Baine MJ; Meza JL; Lin C
    Front Oncol; 2020; 10():1518. PubMed ID: 32983998
    [No Abstract]   [Full Text] [Related]  

  • 17. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor.
    Amin S; Baine M; Meza J; Alam M; Lin C
    Clin Transl Radiat Oncol; 2020 Sep; 24():34-40. PubMed ID: 32613090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma.
    You W; Ke J; Chen Y; Cai Z; Huang ZP; Hu P; Wu X
    Front Immunol; 2022; 13():864244. PubMed ID: 35720314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
    Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapeutic Approaches in Pancreatic Adenocarcinoma: Current Status and Future Perspectives.
    Yee NS
    Curr Mol Pharmacol; 2016; 9(3):231-241. PubMed ID: 26177643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.